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Abstract 
Integration of Hepatitis B virus (HBV) DNA is frequently detected in HBV-
associated hepatocellular carcinoma (HCC). Despite a strong association between viral 
DNA integration and the development of HCC, the effect of viral insertions in the liver 
carcinogenesis remains largely unclear. In an effort to gain insight into the HBV DNA 
integrations in HCC development, HBV integrants in HCC were examined by the high-
throughput restriction site polymerase chain reaction (RS-PCR). A total of 115 specimens, 
including 15 HBV-positive HCC cell lines, and 50 pairs of primary HCC derived from 
chronic carriers of HBV and their surrounding non-malignant liver, were investigated. 
Among the 50 pairs of tumors and their respective adjacent non-malignant counterparts, 
33 cases were derived from a cirrhotic liver, while 17 cases were derived from a 
background of chronic hepatitis. 
HBV integration into the host genome was indicated in 13 HCC cell lines, 27 
HCC tumors and 16 adjacent non-malignant livers. More frequent integrations were 
found in tumor than adjacent non-malignant liver with significant differences observed in 
the non-cirrhotic group (p<0.016). A total of 91 integration sites were mapped and 
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sequenced; 23 sites were identified in HCC cell lines, 42 sites in the primary HCC tumors 
and 26 sites in non-malignant liver. Different chromosomal locations and cellular genes 
were found in the HBV insertional events. Intriguingly, almost all interrupted cellular 
genes identified in this study were mapped to the intronic or non-coding regions of the 
human genome. Besides, integrations frequently occurred in the vicinity of repetitive 
sequences, where the AT content was significantly higher than the GC content. The 
locations of HBV insertions were also often found near common fragile sites. Regarding 
the viral junctions, frequent integrations involving a breakpoint within a 500bp sequence 
between the core and HBx region in the HBV genome were observed. 
In summary, although HBV insertion sites were distributed randomly in the 23 
human chromosomes, the cluster of integrations into non-coding regions and fragile sites 
suggested that HBV integration might not be a random event and that these cellular DNA 
sequences may share similarities that favored HBV integration. Viral DNA integrations 
into the host genome may play critical roles in altering cell growth and/or viral 
proliferation that promoted HCC development. Consistent with the notion that HBx is a 
transactivator of host cellular genes and plays a causative role in HCC, the recurrent 
integration of truncated HBx sequences into the HCC genomes observed in this study 
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Hepatocellular carcinoma (HCC) is one of the most common malignancies, 
representing more than 5% of all cancers. It currently ranks as the fifth most common 
cancer in the world and the third most common cause of cancer mortality (Parkin 2001). 
The estimated annual number of cases exceeds 560,000 globally and an almost equal 
number of deaths (550,000). The incidence of HCC varies considerably with the 
geographic area in Northern Europe, Australia, New Zealand and the Caucasian 
populations of North and Latin Americas have a lower incidence rate, whereas, China, 
Southeast Asia and sub-Saharan Africa have the highest incidence rates that contribute 
the great majority of cases (>80%) per annum. Differences in exposure to various risk 
factors are likely to account for the wide geographical variation in incidence. Moreover, 
the overall incidence of HCC found in males is higher than in females, with a male to 
female ratio of 4.1 to 1.0. 
In Hong Kong, HCC is currently the fourth most common cancer (Table 1-1). It is 
the second leading cause of cancer mortality in males and the seventh most common in 
females. In both genders, a high mortality to incidence ratio is observed (0.85 in males 
and 0.86 in females). Moreover, the five-year survival rate of HCC patients is very low, 
which is attributed largely to the aggressive characteristics of the tumors (Stewart 2003). 
The major risk factor for HCC development is the existence of liver cirrhosis, 
regardless of its etiology (Zaman et al. 1985). Besides cirrhosis, viral hepatitis infections, 
and high alcohol intake are also associated with the risk of HCC development. (Colombo 

















































































































































































































































































































































































































































































































1.2 Etiological factors of hepatocellular carcinoma (HCC) 
The exact mechanisms underlying the neoplastic transformation of HCC are still 
not well understood, although several etiological factors are now well-recognized in liver 
tumorigenesis. These factors include chronic viral hepatitis (Type B and C) infections, 
dietary alfatoxin exposure, alcoholic liver disease, nonalcoholic steatohepatitis, age and 
the male gender. The risk factors for HCC vary by regions, differences in the geographic 
prevalence of viral hepatitis and the dietary contaminant aflatoxin have contributed to the 
high incidence of HCC in countries such as China, South Korea, Japan, Singapore, parts 
of Europe and Africa (Figure 1-1). 
1.2.1 Dietary Aflatoxins 
Aflatoxin Bi (AFBl) is a mycotoxin produced by fungi of the Aspergillus species, 
which grows on crops, such as com and peanuts that have been stored in warm, damp 
conditions. AFBl is known to be a powerful hepatic carcinogen in the development of 
HCC (lARC Working Group 1987). The geographic distribution of aflatoxin contaminant 
has been reported in areas such as sub-Saharan Africa, Southeast Asia and South America. 
These areas are also countries with high incidence of HCC. (Ozturk 1991; Sylla et al. 
1999) 
AFBl is believed to exert adverse effects on the human genome by inducing 
chromosome breaks, abnormal sister chromatid exchange and chromosomal instability 
(Wang and Groopman 1999). The metabolite of AFBl has been shown to bind and 
damage DNA, primarily at the N7 position of guanine (Gamer et al. 1972). The 
4 
characteristic genetic change associated with AFBl is the frequent mutation on the p53 
tumor-suppressor gene. A nucleotide G to T transversion (Foster et al. 1983) in the third 
base ofcodon 249 resulting in a AGG^^^ to AGT^^^ mutation has been observed in HCC 
tumors arising in individuals living in high aflatoxin areas (Bressac et al. 1991; Hsu et al. 
1991). 
1.2.2 Liver Cirrhosis 
Hepatitis virus infection, increased alcohol intake, hereditary hemochromatosis, 
a 1-antitrypsin deficiency and antoimmue hepatitis can induce impaired liver function and 
cirrhosis (Fattovich et al. 2004). A cirrhotic liver is pathologically characterized by the 
loss of normal microscopic lobular architecture, with fibrosis and nodular regeneration. 
The presence of large cell change (Borzio et al. 1995; Ganne-Carrie et al. 1996; Degos et 
al. 2000)， irregular regeneration of hepatocytes (Shibata et al. 1998)， and 
macroregenerative nodules have been implicated as morphogic predictors of HCC 
development in a cirrhotic liver. 
Liver cirrhosis is an important risk factor for the development of HCC. 80% to 
90% of HCCs arise from a cirrhotic background (Resnick and Koff 1993; Vauthey et al. 
2002). It is suggested that liver cirrhosis is a pre-cancerous condition that drives HCC 
development. The malignant transformation of hepatocytes from liver cirrhosis has been 
suggested to be related to the TGF beta-induced extracellular matrix remodeling 
(Jaskiewicz et al. 1993; Le Bail et al. 1997; Iredale 2003). 
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1.2.3 Alcohol Abuse 
Heavy alcohol consumption for prolonged time periods is a risk factor for HCC 
development. A relationship between the risk of HCC and alcohol intake was suggested 
between HCC patients and individuals unaffected by hepatic diseases (Donato et al. 
2002). Alcohol is strongly associated with the development of liver disease such as 
cirrhosis, although there is little evidence for a direct carcinogenic effect (Ruddon 1987). 
There is evidence for a synergistic effect of heavy alcohol consumption and viral 
hepatitis B or C on the risk of cirrhosis and HCC (Donato et al. 2002). Presumably, these 
factors operate together to increase the risk of HCC by more actively promoting liver 
cirrhosis. In addition, alcoholic abuse was suggested to be associated with an increased 
susceptibility to hepatitis B infection via ethanol-mediated stimulation of viral gene 
expression and replication (Larkin et al. 2001). 
1.2.4 Viral Hepatitis Infection 
The hepatitis B (HBV) and hepatitis C (HCV) viruses are the major etiologic 
factors for HCC development. Both can cause a wide spectrum of clinical manifestations, 
ranging from healthy carrier state to acute and chronic hepatitis, cirrhosis and especially 
HCC. HBV and HCV can promote HCC development in an indirect way, through 
induction of inflammation, necrosis and chronic hepatocellular regeneration. Besides, the 
virus can also promote HCC directly by means of viral proteins or, in the case of HBV by 
creating insertional mutations into the hepatocyte genome. Chronic hepatitis infection is 
believed to be related to continuous or recurring cycles of hepatocyte necrosis and 
regeneration (Kew 1996). This results in accelerated cell turnover, which may act as a 
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tumor promoter by increasing the probability of spontaneous mutations or damage to 
DNA by exogenous factors. The accelerated turnover rate may facilitate mutations in 
propagated cells, which escape from DNA repair mechanisms and lead to uncontrolled 
liver cell growth and eventual malignant cell transformation (Chisari et al. 1989; Idilman 
et al. 1998). Another mechanism of malignant transformation is the generation of 
mutagenic reactive oxygen species from the inflammatory process, such as nitric oxide 
(NO), superoxide anion (O2), hydroxyl radical (OHD) and hydrogen peroxide (H2O2) 
(Kew 1998). Moreover, the viral protein may produce severe and prolonged injury to the 
hepatocytes, leading to inflammation, regenerative hyperplasia and transcriptional 
deregulation that can ultimately lead to neoplasia (Chisari et al. 1989). 
1.2.4.1 Hepatitis B Virus (HBV) 
Epidemiological data provide compelling evidence for a role of HBV in the 
development of HCC. It is estimated that 2 billion people have been infected with HBV 
worldwide and 360 million suffer from chronic HBV infection. HBV infection is a major 
health problem in areas such as Southeast Asia and sub-Saharan Africa. It is well known 
that the risk of developing HCC in chronic HBV carriers is 100 times higher than those 
without HBV infection (Beasley 1988). Therefore, the incidence of HCC is higher in 
areas where HBV is edemic. 
Hepatitis B virus is a partially double stranded hepatotropic DNA virus classified 
in the virus family of Hepadnaviridae. It is one of the smallest human viruses with a 
circular structure and a genome size of only 3.2kb (Figure 1-2). The entire nucleotide 
sequence has been classified into 8 genotypes (A-H), with predominance of the 
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genotypes A and D in Western countries and Types B and C in Southeast Asia and the 
Far East (Okamoto et al. 1988; Norder et al. 1994; Stuyver et al. 2000; Arauz-Ruiz et al. 
2002). Although HBV is a DNA virus, it replicates like a retrovirus through an RNA 
intermediate and requires an active viral reverse transcriptase (RT) (Figure 1-3). It enters 
the livers perinatally, or via bloodstream, body fluids or sexual contact. 
The vims encodes a small number of known gene products, including DNA 
polymerase, hepatitis B core protein (HBcAg), envelope protein S (HBsAg), L and M, as 
well as proteins such as hepatitis B X protein (HBx) and hepatitis B e antigen (HBeAg). 
HBV consists of an outer envelope and an internal core (nucleocapsid). The envelope is 
composed mainly of envelope proteins, which play a central role in the immunodiagnosis 
of HBV infection. The nucleocapsid contains the viral core protein and DNA polymerase, 
which is of central importance to vial replication. The physiological role of HBx in the 
viral life cycle is still largely unclear, but it is believed to be involved in the productive 
infection of the virus. For HBeAg, it is produced by posttranslational modification of 
HBcAg, which serves as a seromarker for the increased levels of viral replication. 
Apart from the inflammation followed by recurring hepatocye necrosis and 
regeneration, and liver cirrhosis, a significant proportion of HBV-related HCCs arise in 
an otherwise normal liver, implicating the virus as exerting a direct oncogenic effect on 
the HCC development (Kew 1998). It is believed that HBV can also induce HCC 
indirectly by causing chronic inflammatory hepatic disease and continuous or recurrent 
cycles of hepatocyte necrosis and regeneration that may result in malignant 
transformation. The increased cell turnover rate may also promote carcinogenesis 
through accumulation of spontaneous mutations and DNA damage. Besides, integration 
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of HBV genome into the hepatocyte genome has also been suggested to play a role in 
the carcinogenesis of HCC. Integration of HBV into the host genome was found in 80% 
to 90% of HBV-related HCC patients and clonal expansion of the viral insertion sites 
has been observed (Laskus et al. 1999; Zhong et al. 2000; Ng et al. 2003). Moreover, the 
integration may dysregulate the regulatory mechanisms of cell cycle by causing 
chromosomal abnormalities and alteration, or production of viral proteins that can 
accelerate the development of HCC. Integration of the viral genome into the host may 
increase chromosomal instability and, hence, promote chromosome recombination, 
which in turn may increase the risk of HCC development. Active replication of HBV 
may also initiate malignant transformation through a direct carcinogenic mechanism by 
increasing the probability of insertion of viral DNA. 
i 
The HBV integration process appears to involve recombination mechanisms that 
do not preserve the viral genome sequence. The integration of viral DNA may increase 
the production of HBx protein, which is a potent transactivator of several signaling 
pathways and, hence, contributes to HCC transformation. 
1.2.4.2 Hepatitis C Virus (HCV) 
Chronic infection with Hepatitis C virus is also a major risk factor for the 
development of HCC. HCV is one of the major public health problems and more than 
170 million people are infected worldwide (Buendia 2000). HCV infection also 
demonstrates preferential geographical distribution and it is most prevalent in Japan, 
Southern Europe and some African countries such as Egypt, although there is also an 
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increasing incidence in Western countries in recent years. Approximately 80% of HCV 
infected patients develop chronic hepatitis C. 
HCV has been classified as the Hepacivirus genus of the Flaviviridae family 
(Koff 2000). HCV infection is believed to be transmitted mainly through direct contact 
with infected blood. It is a linear RNA virus of approximately 9.6kb nucleotides length. It 
includes 6 major genotypes (Simmonds et al. 1993) and encodes a single polyprotein 
precursor of about 3000 amino acids that is cleaved into several smaller structural (core, 
envelope 1, 2) and non-structural (NSl, NS3, NS4A, 4B, NS5A, 5B) proteins. These 
proteins are necessary for the replication of the virus (Szabo et al. 2003) (Figure 1-4). 
The pathological features associated with HCV are similar to those by HBV 
including acute and chronic hepatitis, cirrhosis and HCC. The virus has no reverse 
transcriptase enzyme and does not integrate into the host genome. The molecular 
pathogenetic mechanisms by which HCV contributes to malignant transformation of the 
cell remain unclear. Similar to HBV, HCV infection may cause inflammatory action of 
the host and, hence, induces several liver disease (Yano et al. 1996), which may in turn 
increase the risk of HCC. 
A direct oncogenic action of HCV has also been proposed in promoting 
hepatocarcinogenesis, where the viral replication may cause inappropriate expression of 
transforming growth factor-a and insulin-like growth factor II (Nardone et al. 1996); 
(Tanaka et al. 1996). The core protein of HCV has a suggested role in liver 
carcinogenesis, since its presence in a transgenic mice model has been able to induce 
HCC development (Kim et al. 1991). It may function as a gene regulator (Shih et al. 
1993); (Kim et al. 1994) and is responsible for HCV-induced hepatic steatosis (Moriya et 
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al. 1997). HCV core protein has been described in the inhibition of tumor suppressor 
genes such as p53, which has been demonstrated in hepatic oncogenesis (Ruster et al. 
1996; Ray et al. 1997; Ray et al. 1998). The expression of HCV core protein can also 
modulate various cellular signal transduction pathways by mediating the transcriptional 
activity of N F K B and STAT-3 proteins (Waris and Siddiqui 2003). It has been shown that 
the induction of nuclear factor KB (NF-KB) by HCV core protein could suppress the TNF-
a-induced apoptosis (Tai et al. 2000). This anti-apoptotic event may be a possible 

































































































Figure 1-2 The genomic structure of hepatitis B virus 
Abbreviation: S: surface antigen; DR: direct repeat segment 
The inner circles represent the minus (-) and (+) DNA strands of the viral genome. The 
HBV polymerase is shown as an orange circle covalently bound to the 5'-end of the (-) 
DNA strand. The nucleotide numbering of the genome is based on the unique EcoRI 
restriction enzyme site shown. The different open reading frames encoding by the 
genome, designated as S, core, polymerase, and X, are indicated by the arrows. 
Nucleotide numbers designate the boundaries of each ORF with position 1 mapped at the 
EcoRI site. Shown also are the map positions for the viral direct repeats (DRl and DR2 
for DNA replication). 
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Figure 1-3 The Life Cycle of HBV. 
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1.3 Literature Review on the Investigations of HBV Integrants in 
HCC 
Viral integrations have been reported in the pathogenesis of cancers such as HPV 
integration in cervical cancer (Jeon and Lambert 1995). Integration of HBV DNA into the 
host genome is frequently found in HCC (Hino et al. 1991). However, the precise 
mechanisms of integration of viral DNA are still not clearly understood, and many efforts 
from various groups have been put into understanding the role and mechanism of HBV 
integrations in promoting liver carcinogenesis. 
Integration of HBV DNA into the host genome has been investigated by different 
groups over the past decades. Viral integration was first identified by Southern blotting in 
the 1980’s and results suggested the monoclonal or oligoclonal proliferation of cells 
containing HBV DNA (Miller and Robinson 1986; Blum et al. 1987; Brechot 1987). 
However, findings from Southern blotting are of relatively low resolution. Only patterns 
of integration could be observed and the exact chromosomal location of the vims host 
junctions could not be obtained. 
Subsequent PCR-based methodologies such as inverse polymerase chain reaction 
(IPCR), cassette ligation mediated PGR, Alu-PCR and genomic library screening have 
indicated molecular information on the HBV integrants. Information on viral host 
junctions was obtained, although both IPCR, cassette ligation mediated PCR and 
genomic library screening were low throughput and technically cumbersome. The Alu-
PCR was frequently associated with the identification of Alu repeat sequences. 
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1.3.1 Affected Host Junctions 
Although prevalence of preferential integration sites is not apparent in humans, 
studies have indicated frequent insertions of HBV DNA within or close to key oncogenic 
cellular genes in human HCC. Cellular genes identified include retinoic acid receptor 
beta {RARP) (Kekule et al. 1990), cyclin A (Paterlini-Brechot et al. 2003)， 
Sarcol/Endoplasmic Reticulum Calcium ATPase-1 (SERCAI) (Berasain et al. 1998), 
nuclear matrix protein p84 (Garcia et al. 1993), human telomerase reverse transcriptase 
QiTERT) (Urano et al. 1991; Garcia et al. 1993; Chami et al. 2001)，neutrotrophic tyrosine 
receptor kinase 2 (Urano et al. 1991) and inositol 1,4,5-triphosphate receptor type 1 
(Urano et al. 1991). Moreover, functional studies have demonstrated that HBV DNA-
related RARp and cyclin A insertional mutagenesis has transforming activity in vitro and 
in vivo (Hino et al. 1986; Wang and Rogler 1988), and the ectopic expression of 
HBV/SERCAl fusion transcripts has a role in cell growth and survival (Tokino et al. 
1987). These studies of HBV-related insertional mutagenesis have allowed the isolation 
of previously imdescribed human genes in the cellular differentiation and proliferation 
with a proven role in liver carcinogenesis. 
Integration of the HBV genome can induce chromosomal instability, translocation 
and deletions at the site of insertion (Blum and Moradpour 2002). The predominant role 
of the viral integration event has been further implicated in the initiating conditions of 
overall genomic instability that ultimately results in oncogene activation and tumor 
suppressor inactivation, leading to the development of cancer. Indeed, small deletions of 
few base pairs in the cellular DNA have been demonstrated at sites of HBV insertions in 
HCC, although major chromosomal deletions associated have been suggested on 4q, 1 Ip 
17 
and I6q (Slagle et al. 1991; Pineau et al. 1998). Translocations have also been described 
at the integration sites. These rearrangements include t(X;17), t(5;9), t(17;18) and t(3;8) 
(Hino et al. 1986; Tokino et al. 1987; Pineau et al. 1998). Furthermore, HBV DNA 
insertion has also been identified at locus 17pl3 near the p53 gene (Slagle et al. 1991). 
1.3.2 Viral Junctions 
Apart from the human junctions of the HBV insertion sites, the viral junctions of 
the insertional sites have also been reported in previous studies. Integration of HBV DNA 
via the 2 direct repeat (DRl and DR2) sequences located in the X and core region of the 
HBV genome, was frequently found (Dejean et al. 1984; Yaginuma et al. 1985; Hino et al. 
1991). Disrupting these two regions might facilitate the production of truncated X protein, 
which is believed to have much significance in promoting HCC development. 
Apart from the HBx protein, the sequence of pre-Sl of HBV can also stimulate 
the transcription of transforming growth factor a (TGFa). Coexpression of TGFa and 
HBsAg could accelerate hepatocellular carcinogenesis by stimulating hepatocyte 
proliferation (Jakubczak et al. 1997). The preS2/S gene integrations have been reported in 
HBV-associated HCCs. The 3'-truncated PreS2/S could produce a truncated protein, 
which could be oncogenic and possessed trans activating activity on proto-oncogenes 
such as c-myc and c-fos (Kekule et al. 1990), 
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1.4 Restriction Site Polymerase Chain Reaction (RS-PCR) 
Restriction Site Polymerase chain reaction (RS-PCR) was employed in the present 
study for the identification of HBV integration sites. RS-PCR utilizes specially designed 
primers that recognize, anneal, and sustain PGR. These primers, termed restriction site 
oligonucleotides (RSOs), can be generated corresponding to any restriction enzyme 
recognition sequence irrespective of the length of the recognition site and used as PGR 
primers corresponding to the unknown region of a DNA segment (Sarkar et al. 1993). 
This technique was previously employed in isolating and investigating the viral 
integration sites in several cancers, including Human Papillomavirus virus (HPV) 16 
integration in cervical cancer (Ferber et al. 2003; Thorland et al. 2003) and head and neck 
cancer (Ragin et al. 2004)，and HBV integration in HCC (Ferber et al. 2003). The results 
from these studies showed that RS-PCR enabled the isolation of viral integration sites, 
which consist of an unknown human nucleotide sequence and known viral sequences 
successfully. RS-PCR is both high resolution and high throughput in analyzing sequences 
of viral integrants. 
A small study on the identification of HBV viral integration sites in HCC cases 
has been previously reported by RS-PCR (Ferber et al. 2003). Although viral junctions 
were suggested, HBV-specific primers designed in that study were based on one HBV 
full-length sequence recovered from chimpanzees. In this study, human-specific HBV 
sequences were employed in designing the HBV primers. A total of 56 HBV sequences 
were aligned and consensus sequences were obtained for the primer design. Among the 
56 sequences, most of them were obtained from patients in Hong Kong and China 
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(genotypes B and C) so that the specificity and success rate In isolating the HBY 
integrants in patients from our locality can be increased. 
20 
1.5 Aims of Thesis 
Hepatitis B virus (HBV) integration into the host DNA can be detected in 80-90% 
of HBV-related hepatocellular carcinoma (HCC). The majority of HCC tissues also 
exhibit clonal expansion of tumor cells carrying the same integration site. Implication of 
the importance of viral integrants in the development of HCC has, thus, been suggested, 
although details on the induction of carcinogenic changes in the liver remain unclear. The 
isolation and characterization of HBV integrants are, therefore, expected to provide 
insight into our understanding of HBV infection in HCC development. 
The present study can be broadly divided into 3 parts. The first objective is to 
evaluate the efficacy of the high throughput, high resolution technique of RS-PCR in the 
identification of flanking human sequences in HCC. To this end, investigation in 15 
HBV-related HCC cell lines was performed and refinement of the screening technique 
was also carried out. 
The second objective of this thesis is to further identify HBV integration sites in 
primary HCC and corresponding non-malignant livers from 50 HBV-related HCC 
patients. This aimed at characterizing the virus host junctions in tumors and adjacent non-
malignant livers. Moreover, the 50 cases recruited included those arising from a cirrhotic 
and non-cirrhotic background. 
The third objective aimed at defining HBV insertional sites from the results 
obtained from cell lines and primary HCC. Recurrent sites or cellular genes involved in 









4',6-Dimamidino-2-phenylindole (DAPI) Sigma Chemical Company 
Acetic Acid Fisher Scientific 
Agarose, regular Biowest 
Amplification Diluent NEN Life Sciences 
Dimethyl sulfoxide (DMSO) Sigma Chemical Company 
Ethanol Analytical Grade Fisher Scientific 
Ethidium bromide Sigma Chemical Company 
Ethylenediaminetetracetic acid (EDTA) Sigma Chemical Company 
Formamide Intergen Compnay 
Hi-Di formamide Amersham Biosciences 
Hydrochloric acid (HCl) Fisher Scientific 
Hydrogen Peroxide Solution (H2O2) about 
30% BDH Laboratory Supplies 
Isoproponol Analytical Grade Fisher Scientific 
Potassium chloride Sigma Chemical Company 
LB broth Amersham Biosciences 
Methanol Analytical Grade Fisher Scientific 
NEN blocking reagent NEN Life Sciences 
Phenol/Chloroform/isoamyl alcohol 
25:24:1 (v:v:v) Gibco Invitrogen Company 
SephadexTM G-50 Fine DNA Grade Amersham Biosciences 
Sigma Water Sigma Chemical Company 
Tween 20 Sigma Diagnostics 
Vectorshield anti-fade reagent Vecta Labs 
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2.1.2 Buffers 
Reagents Company / reciepe 
Phosphate buffer saline (PBS), pH7.4 Sigma Chemical Company 
Tris acetate EDTA buffer (TAE), pH7.4 Sigma Chemical Company 
T^MA r^  + , D 议 IM Tris-HCl, pH 8.0, 0.5M EDTA, DNA Extraction Buffer jt … aH20 
Sodium chloride-sodium citrate 3M sodium chloride, 0.3.M sodium 
concentrate (SSC) (20X) citrate, pH7.0 
^ t t L rr O.IM Tris-HCl, pH7.6, 0.15M NaCl, TNT buffer ^ t � a 
0.05% Tween 20 
O.IM Tris-HCl, pH7.6, 0.15M NaCl, 
iJN IB butter 0.5% NEN blocking reagent 
2.1.3 Cell cultures 
Reagents Company 
AIM-IV Gibco Invitrogen corporation 
DMEM Gibco Invitrogen corporation 
RPMI 1640 Gibco Invitrogen corporation 
Fetal calf serum (FBS) Gibco Invitrogen corporation 
Penicillin and streptomycin Gibco Invitrogen corporation 
Trypsin BD Labware Company 
Tissue culture flask (150, 75, 25 cm】） BP Labware Company 
2.1.4 Nucleic acids 
Reagents Company 
All custom designed oligos Gibco Invitrogen Corporation 
Biotin-16-dUTP Boehringer Mannheim 
Deoxynucleotide Triphosphate Set, PCR 
grade Roche Diagnostics Corporation 
Human Co-I DNA Gibco Invitrogen Corporation 




AmpliTaq Gold DNA Polymerase Applied Biosystems 
BamHI Amersham Biosciences 
DNA Polymerase I Amersham Biosciences 
Exonuclease I Amersham Biosciences 
Expand Hi-Fi Taq Polymerase Roche Diagnostics Corporation 
Pepsin Boehringer Mannheim 
Proteinase K recombinant, PGR grade Roche Diagnostics Corporation 
RNase Boehringer Mannheim 
Shrimp, Alkaline Phosphatase Roche Diagnostics Corporation 
Taq Polymerase Qiagen Inc. 
2.1.6 Equipment 
Reagents Company 
96-Well GeneAmpO PGR system 9700 Applied Biosystems 
CM3000-Cryostat Leica Corporation 
Leitz DM RB fluorescence microscope Leica Corporation 
Leitz DM RE fluorescence microscope Leica Corporation 
GeneQuant Pharmacia Biotech 
Gel Doc Bio-Rad Laboratories, Inc 
SkyVisionO Spectral Imaging System Applied Spectral Imaging Ltd. 







































































































































































































































































































































































2.2.1 DNA Extraction 
2.2.1.1 Cell lines 
Genomic DNA of cell lines was extracted using phenol/chloroform. The cell 
pellet collected was washed twice by PBS prior to lysing in extraction buffer. Proteinase 
K was added to a final concentration of 250|j,g/ml. After overnight incubation at 56°C, 
RNase was added to the cell solution to a final concentration of 500|j.g/ml and the whole 
lysate was further incubated for an additional 24 hours at 37°C. Phenol/chloroform was 
then added in equal volume to the lysate, which was then shaken at room temperature for 
2 hours. The solution was then centrifuged for 15 minutes at 4500rpm at 4°C and the 
upper aqueous layer was carefully collected. One-tenth volume of 3M sodium acetate and 
2.2 times volume of cold absolute ethanol were added to the aqueous solution, mixed by 
inversion and DNA was then allowed to precipitate at -20°C overnight. The final DNA 
pellet was collected by centrifiigation at 13,000rpm for 10 minutes at 4°C. The 
supernatant was discarded, and the DNA pellet was washed twice by 75% ethanol. The 
DNA pellet was then air dried and finally resuspended in double distilled water prior to 
storage at -20°C. 
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2.2.1.2 Primary HCC Tissues 
Genomic DNA of primary HCC tumors was extracted using QIAamp DNA Mini 
Kit (Qiagen, GmbH Germany). Tumorous liver tissues embedded in OCT compound was 
sectioned by CM-3000 Gyrostat (Leica Corporation). Sectioned tissues were washed in 
cold PBS prior to centrifligation at 6000rpm for 5 minutes. The tissue sections were 
washed once more in cold PBS and then processed for DNA extraction according to the 
Tissue Protocol of QIAamp DNA Mini Kit (Qiagen Qiagen, GmbH Germany). 
The purity of extracted DNA was evaluated by gel electrophoresis (Figure 2-1). 
The concentrations of DNA were measured by GeneQuant (Pharmacia Biotech) and the 
quality was evaluated by the nucleotides acids to protein ratio (A260/280). Only samples 
with DNA ratio >1.8 were used in this study. Samples with suggested residual protein / 
RNA were subjected to re-extraction. 
The quality of DNA was also checked by amplifying the p-globin gene using 
specific primers (Forward primer: 5,-GAA GAG CCA AGG ACA GGT AC-3’，Reverse 
primer: 5，-CAA CTT CAT CCA CGT TCA CC-3,). Only DNA samples successfully 
amplified for this gene were used for subsequent RS-PCR studies. Examples of the p-
globin gene amplification in genomic DNAs extracted are shown in Figure 2-2. 
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Figure 2-1 DNA quality checked by 1% agarose gel electrophoresis 
Genomic DNA 
Marker HCCl HCC2 
2kb HjUm^^^^^^^^^^^^^^H 
— • 
Gel photo showed the absence of the RNA and protein in the genomic DNA extracted. 
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Figure 2-2 PCR amplification of P-globin gene in genomic DNA extracted 
HCC samples 




Quality of DNA extracted was verified by PCR amplification of p-globin gene. Distinct 




Viral integration leads to the juxtaposition of viral sequences adjacent to the 
human genomic sequence. In this study, the Restriction-Site Polymerase Chain Reaction 
(RS-PCR) was used to amplify the host cellular sequences flanking the viral insertional 
sites. The advantage of RS-PCR is that it enables the amplification of unknown 
nucleotide sequences adjacent to known nucleotide sequences with the use of restriction 
site oligonucleotide primer (ROS primer) (Figure 2-3). (Sarkar et al. 1993; Weber et al. 
1998; Ferber et al. 2003; Thorland et al. 2003). The RSO primer incorporates (from 5’ to 
3，）a T7 RNA polymerase promoter recognition site, which enables cloning of the 
integrants for the identification of second virus host junction, 10 degenerate nucleotides, 
and six bases specific for a chosen restriction endonuclease site. Sequences of the RSO 
primers used are listed in Table 2-1. 
In order to ensure specificity, the RS-PCR procedure included a set of nested 
primers specific to the viral genome. In this thesis, 8 HBV primers at approximate 
intervals of 300bp - 500bp apart throughout the 3.2kb HBV genome were designed. The 
primers, 4 each in opposite directions, flanked the two direct repeat sequences, DRl and 
DR2, that were within the X and core regions, where integrations of the HBV into host 
genome have been frequently reported. 
As HBV genome sequences varied with genotypes, 56 HBV full length sequences 
obtained from patients with chronic hepatitis B virus (mainly genotypes B and C) were 
aligned and consensus regions were used for HBV primers design. The design of primers 
is shown in Figure 2-4 and the primer sequences are listed in Table 2-2. 
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Genomic DNA was subjected to two rounds of nested RS-PCR prior to 
sequencing. First round RS-PCR was performed at the permissive annealing temperature 
of 45°C, followed by a nested second-round PGR with a more stringent annealing 
temperature of 55�C. For all samples examined in this thesis, lOOng of DNA were 
combined with 2pmol each of HBV-specific primer, 20pmol of RSO primer, lOx PGR 
buffer (Roche Diagnostics) containing 1.5mM MgC12, 200mM deoxynucleotide 
triphosphates (dNTPs), and 0.14U of Expand Hi-Fi Taq Polymerase (Roche Diagnostics, 
Indianapolis, IN, USA) in the first ？ound reaction. In 2"�round PGR, 2\x\ of the 严 round 
PGR product was combined with 2pmol of each HBV-specific primer, 20pmol of RSO 
primer, lOx PGR buffer containing 200mM dNTPs, and 0.2U of Taq DNA Polymerase 
(Qiagen GmbH, Germany) in a 20|al reaction. After denaturation of 2 min at 94�C，cycles 
of 30s at 94°C，30s at 45°C (first round of PGR) or 55�C (nested PGR), and 3 min + 20s 
per cycle at 68°C for 25 cycles, and final extension for 10 min at 72°C were performed. 
The RS-PCR was performed using ABI 96-Well GeneAmp® PCR system 9700 (Applied 



































































































































































































































































































































































































































































Table 2-1 Sequence of RSO primer used in RS-PCR 












Table 2-2 Sequence of HBV-specific primers for RS-PCR and sequencing of the 
HBV integrants 
Primer Code HBV Region Primer Sequence (5'-->3') 
Round 1 RS-PCR 
HBV-F1-1 X gene TGCTGCCAACTGGATCCTGCG 
HBV-F2-1 Polymerase CTCGCC AACTTAC AAGGCCTTT 
HBV-F3-1 Surface TTCAGTGGTTCGTAGGGCTTTCC 
HBV-F4-1 Surface CAGGCGGGGTTTTCCTTGTTGAC 
HBV-R1 -1 Core GG AGCTTCTGTGG A ATTACTC 
HBV-R2-1 Core TCGC AGAAGATCTC AATCTCGGG 
HBV-R3-1 Polymerase ATGGGGACGAATCTTTCTG 
HBV-R4-1 PreS2 TCTCCACCTCTAAGGGACA 
Round 2 RS-PCR 
HBV-F 1 -2 X gene ACGTCCTTTGTTTACGTCCCGTC 
HBV-F2-2 Polymerase TGAACCTTTACCCCGTTGC 
HBV-F3-2 Surface TGGCTTTCAGTTATGTGGATG 
HBV-F4-2 Surface ACCACAGAGTCTAGACTCGTGG 
HBV-Rl-2 Core GGGGCATGGACATTGACACGTA 
HBV-R2-2 Core CCTCGCAGACGAAGGTCTCAAT 
HBV-R3-2 Pre SI CTTGGGAACAAGAGCTACA 
HBV-R4-2 Pre S2 CACCAATCGGCAGTCAGGAAG 
Sequencing primers 
HBV-F 1 -sequencing X gene TCGGCGCTGAATCCCGCGGACGA 
HBV-F2-sequencing Polymerase TACCCCGTTGCTCGGCAAC 
HBV-F3-sequencing Surface TTGGGGGCCAAGTCTGTACAAC 
HBV-F4-sequencing Surface GTGGTGGACTTCTCTCAATT 
HBV-R 1 -sequencing Core TCC A AGCTGTGCCTTGGGTGGCT 
HBV-R2-sequencing Core AGGTCCCCTAGAAGAAGAACTCC 
HBV-R3-sequencing Pre SI TGTGGGTCACCATATTCTTGGG 
HBV-R4-sequencing Pre S2 CCTCCTCCTGCCTCCACCAAT 
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2.2.3 Sequencing 
PCR products from round nested RS-PCR were subjected to two rounds of 
direct sequencing. Based on the first sequencing result on the whole PCR product, 
distinct bands shown from gel electrophoresis were cut from the gel, extracted for DNA, 
and subjected to a round of direct sequencing to confirm the flanking sites. 
Briefly, 5jal of PCR products were restriction enzyme digested to remove excess 
primers left in the PCR mix. The PCR mix was digested by lU of Exonuclease I 
(Amersham Biosciences) and lU of Shrimp Alkaline Phosphatase (Roche Diagnostics 
Corporation), both enzymes were activated at 37°C for 15 minutes, and later inactivated 
at 80°C for 15 minutes. For the PCR products from selected bands, DNA was purified by 
the Gel Extraction Kit (Qiagene GmbH, Germany) and processed according to 
manufacturer's recommendations. 
DNA sequencing was performed using the ABI BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, USA). The HBV-specific sequencing primer used 
was as described in Table 2-2. In a total volume of l\i\ of DNA was mixed with 
3.2pmol each of sequence-specific primer, 2.25^1 of 5x sequencing buffer and 1.5|al of 
Big Dye Terminator (version 3.1) in a reaction of 15|aL Cycle sequencing was performed 
using ABI 96-Well GeneAmp® PCR system 9700 (Applied Biosystems, USA) and the 
cycling condition was: 96°C for 1 min followed by 25 cycles of 96�C for 10s，50°C for 5s 
and 60�C for 4 min. 
The sequencing PCR products were then purified by spin columns. The column 
was packed with the Sephadex G-50 (Amersham Biosciences) resin to remove residual 
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Big Dye Terminator in the PGR product. The purified DNA was then mixed with 8|j.l of 
Hi Di Formamide, which could maintain the DNA in single strand form. The mixture was 
finally denatured at 95°C for 5 minutes and kept on ice until sequencing. The product was 
electrophoresed on Pop-6™ polymer (Applied Biosystems, USA) in an ABI 310,0 
Genetic Analyzer. 
The entire sequence obtained was then deposited onto the National Center for 
Biotechnology Information BLAST. (http://www.ncbi.nlm.nih.gov/BLAST/) and 
Genbank at UCSC BLAT (http://www.genome.ucsc.edu). Sequence homology searches 
were conducted at the DNA levels using BLASTN algorithms on the HBV genome 
assembly and the human sequences adjacent to the viral insertion. The exact 
chromosomal location corresponding to the human genome was often obtainable. 
2.2.4 Spectral Karyotyping (SKY) 
SKY analysis was performed on metaphases obtained from Hep3B cell lines 
according to the method described by our group (Wong et al. 2000). Prior to 
hybridization, the slides were pre-treated with pepsin in 0.0IM HCl at 37°C. Slides were 
then equilibrated in 2 x SSC，followed by ethanol series of 70%, 80% and 100% for 2 
min each and air dried. Following denaturation by 70% formamide at 69°C temperature 
for 90s, denatured metaphases were subjected to ethanol series and air dried. SKY probe 
mixture (Applied Spectral Imaging, Migdal Ha'Emek, Isreal) was denatured at 95 °C for 5 
min and kept on ice for 5 min. The probe mixture was then pre-annealed for at least 30 
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min at 37°C. After pre-annealing，the probe was ready to hybridize onto metaphase 
chromosomes. 
Hybridization of SKY probe mixture (Applied Spectral Imaging, Migdal 
Ha'Emek, Isreal) onto metaphase chromosomes took place at 37°C in a humid chamber 
for 48 hours. Post-hybridization washes were performed in pre-warmed 50% formamide 
for 5 min, followed by 2xSSC for 5 min at 37°C. Slides were then blocked by 3% Marvel 
in 4xSSC, 0.1% Tween for 30 min at 37�C. Indirect labeled probes were then visualized 
using Cy5- and Cy5.5-conjugated antibodies. Chromosomes were finally counterstained 
by DAPI. The fluorescent signals were detected by a SD200 Spectracube (Applied 
Spectral Imaging). Custom designed optical filter (SKY-1; Chroma Technology, 
Btattleboro, VT) was used to capture the hybridized chromosomes and the spectral 
information obtained was analyzed using Sky View software (version 1.6) (Applied 
Spectral Imaging). More than 20 metaphases were analyzed for each cell line and the 
aberrant chromosome detected was karyotyped according to the ISCN nomenclature 
(Mitelman 1995). 
2.2.5 Fluorescence In situ Hybridization 
2.2.5.1 Clone Preparation 
The HBV plasmid (ATCC 45020D) was purchased from ATCC. Approximately 
0.1 jig of HBV plasmid was added to lOOfal of competent DH5a cells and incubated on 
ice for 30min. Heat shock was then performed at 42°C for 1 min 45 sec followed by 
freeze-shocking on ice for 2 min. Pre-warmed LB broth at 0.9ml was then added, and the 
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transformation mixture was further incubated for 45 min at 37�C. The total mixture of 
100|a.l was then spread onto LB-ampicillin plate coated with 75f.il of 2% Xgal and 15|al of 
IPTG, and allowed to incubate at 37�C overnight. 
The HBV clone was sequence verified. Eight white colonies of the transformants 
were picked from the agar plate with a flame-sterilized inoculating loop and streaked 
directly onto another fresh LB-ampicillin agar plate. After overnight incubation at 37°C, 
single isolated colonies were inoculated in 3ml LB-ampicillin broth and incubated at 
37°C overnight with shaking. The plasmid DNA was harvested by Qiagen plasmid 
miniprep kit (QIAGEN GmbH, Germany) according to manufacturer's protocol. The 
DNA was resuspended in distilled water and then digested by restriction enzyme BamHL 
The product sizes obtained after enzyme digestion were checked by gel electrophoresis 
(Figure 2-5). DNA from colonies with correct product sizes was then subjected to 
sequencing for final confirmation. Briefly, 200-5OOng of DNA template was subjected to 
cycle sequencing reaction using Big Dye Terminator and sequenced on the ABI 3100 
Genetic Analyzer according to procedures described in the previous section (Section 
2.2.3). 
Colonies with full-length HBV sequence were further cultured and extracted for 
large preparation of DNA. Half milliliter of the overnight culture was inoculated into 
250ml of fresh LB broth containing lOOmg/ml ampicillin. The whole culture was 
incubated at 37°C with vigorous shaking for about 12-15 hours. The DNA was harvested 
using the QIAGEN Plasmid Mini Kit (Qiagen GmbH, Germany). 
In FISH analysis, HBV DNA was biotin-labeled indirectly by nick-translation. 
Once the optimal size of DNA fragments between 200bp to 500bp was achieved, the 
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reactions were inactivated by the addition of I/IO volume of 2mM EDTA. The labeled 
probe was added to 70-fold of human Cot-1 DNA and lO^g of salmon sperm DNA prior 
to hybridization onto denatured metaphases of the Hep3B cell line. 
Before hybridization, the probe was denatured at 95°C, then kept on ice for 5 
minutes before pre-annealing at 37°C for at least 30 minutes. 
2.2.5.2 Tyramide Signal Amplification (TSA) 
TSA was used to amplify the weak fluorescence signal generated by the HBV probe, 
since TSA can amplify signals by 100-fold or more. Tyramides are molecules that can be 
deposited onto tissues or chromosomes after oxidization by peroxidase. Tyramide-based 
detection, therefore, always requires a peroxide-conjugated antibody. In this thesis, 
biotin-labeled HBV probe was used in conjunction with avidin conjugated HRP antibody 
(Vector Laboratories) (Tyramide amplification kit, NEN Life Sciences) in the detection 
of hybridized HBV signals. 
One microgram of biotin-labeled HBV probe was hybridized onto Hep3B metaphase 
chromosomes in a humid chamber at 37°C overnight. In order to minimize background, 
all endogenous peroxidase activity was quenched prior to the FISH analysis. The slides 
were washed in 3% hydrogen peroxide (H2O2) in methanol at room temperature for 10 
minutes and then equilibrated in 2X SSC for 5 minutes at room temperature. 
Post-hybridization washes were performed in pre-warmed 50% formamide in 2X 
SSC at 45°c for 5 minutes and then in pre-warmed O.IX SSC at 60°C for 5 minutes. The 
slides were then rinsed in TNT buffer before blocking in TNT containing 0.5% 
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Boehringer blocking reagent (TNTB) (TNT/0.5% blocking reagent supplied in the TSA 
kit) (Tyramide amplification kit, NEN Life Sciences) at room temperature for 30 minutes. 
After blocking with TNTB, the slides were incubated with Strept-Avidin conjugated HRP 
in TNB at a ratio of 1:100 at room temperature for 30 minutes. Later, the slides were 
incubated with tyramide conjugated biotin (tyr-bio) at room temperature for 30 minutes. 
The tyramide used was diluted with Amplification Diluent supplied in the Tyramide 
amplification kit (NEN Life Sciences) at a volume ratio of 1:50. The slides were 
subsequently washed 3 times in TNT buffer for 5 minutes each with gentle shaking in the 
dark to remove unhybridized tyr�bio. The slides were finally incubated with avidin 
conjugated FITC at 1:200 in TNTB for 30 minutes at 37°C to detect the tyr�bio 
hybridized signals. Chromosomes counterstained in DAPI were evaluated for hybridized 
HBV signals under the fluorescence microscope (Leitz DM RB fluorescence microscope, 
Leica Corporation). More than ten metaphases should be examined. Schematic 
representation of the TSA principle is shown in Figure 2-4. 
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Figure 2-5 Gel electrophoresis following BamHI digestion of pAM6-HBV 
Plasmid DNA sample 





pAM6，which contains the full length HBV DNA, was digested by BamHI (4.4kb). Three 
products were generated with sizes 4.4kb, 1.85kb and 1.35kb respectively. The 1.35 kb 
fragment contains coding sequences for HBsAg and most of the polymerase region. The 















































































































































































Investigation of HBV Integration Sites 
in HCC Cell Lines 
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3.1 Introduction 
In this chapter, 15 HCC cell lines that were derived from chronic HBV infected 
patients were investigated for the viral-host junctions by the high throughput analysis of 
RS-PCR. The human flanking sequences isolated were mapped with reference to the 
NCBI BLAST search and the efficiency of 10 RSO primers selected was scored. The 
RSO primers chosen were those restriction sites commonly found in the human genome. 
The RSO primers with higher efficiency in localizing viral integrations were chosen for 
further investigations in primary HCC tissues and paired adjacent non-malignant liver 
described in Chapter 4. 
Besides examining the integration events in cell lines, the structural chromosomal 
change related to the integration was also investigated in one cell line, Hep3B. The 
tyramide signal amplification (TSA) was utilized to amplify the low hybridization signal 
of HBV (< 3.2kb) in FISH analysis, and the result was correlated with information on 
chromosomal rearrangements derived from Spectral Karyotyping. 
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3.2 Materials and Methods 
3.2.1 Cell lines 
Seven HBV related HCC cell lines (SNU 387, SNU 398, SNU 423, SNU 449, 
SNU 475, Hep3B and PLC/5) were purchased from American Type Culture Collection 
(ATCC, Rockville, MD, USA). The ATCC acquired cell lines were cultured in DMEM 
medium supplemented with 10% fetal bovine serum (FBS), lOOU/ml penicillin and 
lOOU/ml streptomycin (Gibco BRL. Grand Island, NY, USA). Eight HCC cell lines were 
established from our laboratory (Pang et al. 2000; Pang et al. 2002). These cell lines 
HKCI-1, 3，4, 5, 6, 7，8，and 9 were derived from chronic carriers of HBV patients and 
were maintained in complete medium containing RPMI 1640 glutamax with HEPES 
buffer supplemented with 10% fetal bovine serum, lOOU/ml streptomycin, 20ng/ml 
selenium, 10|ag/ml transferrin and 10|ig/ml insulin. 
All HCC cell lines were maintained in 37�C incubator supplied with 5% CO2. At 
80% confluence, cells were harvested by trypsin/EDTA and extracted from DNA as 
described in Section 2.1.3. 
3.2.2 RS-PCR 
Ten RSO primers with specific restriction site recognitions for BamHI, EcoRI, 
Ndel, Sau3AI, TaqI, Xbal, Hindlll, Pvul, Sail and Alul were employed. For HBV-
specific primers, 8 primers were designed at an average spanning distance of 300-400bp. 
Details of the primers design have been described in Section 2.2.2. Using all possible 
47 
combinations of RSO primers and HBV-specific primers, each sample was hence 
subjected to 80 RS-PCR assays. 
The PGR products from the nested RS-PCR were subjected to a first round of 
direct sequencing. The presence of both viral sequences and human sequences would be 
suggestive of an insertional site. A second round of confirmatory sequencing was 
subsequently performed. Distinctive bands from gel electrophoresis were excised, 
extracted for DNA and sequenced for in a round of sequencing. The procedure of 
DNA sequencing was performed according to methods described in Section 2.2.3. 
3.2.3 Spectral Karyotyping 
SKY analysis on Hep3B cell line was performed according to procedures 
described in Section 2.2.4. 
3.2.4 Tyramide Signal Amplification for HBV in FISH Analysis 
HBV DNA was extracted from plasmid pAM6 (ATCC 45020D), which is a 
recombinant plasmid containing the complete 3.2kb HBV genome (subtype adw) that has 
been cloned into pBR322 at the BamHI site (Figure 3-1). 
Prior to FISH analysis, the full-length HBV sequence was first sequence-verified. 
The procedure and primer sequences were as described in Section 2.2.5.1. As the size of 
the HBV genomic DNA is only 3.2kb, FISH signals generated would inevitably be too 
small for the naked eye to differentiate signal from background. In this study, the 
tyramide signal amplification (TSA) technique was employed to amplify the HBV 
hybridized signal. The principle and procedure of in situ hybridization based TSA 
performed has been described in Section 2.2.5.2. 
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Figure 3-1 Restriction map of pBR 322 
B a m H I 广\ 
PBR322 
I 4361 bp 
V y 
Recombinant plasmid pAM6 containing the complete genome of HBV was cloned at the 
BamHI site of this vector. Primers were designed at the BamHI site of the vector and full-
length sequences of HBV were confirmed by DNA walking starting from the BamHI site. 
Primers used were as described in Table 3-1. 
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Table 3-1 Primers for verification of HBV sequences in pAM6 
Primer Code Region Primer Sequence (5'-->3') 
pBR322-L GTCACTATGGCGTGCTGCTA 
pBR322-R GGTGATGTCGGCGATATAGG 
pBR322_F3-l-L Polymerase/ X CCTCCTCGCGGAAATATACA 
pBR322_F3-l-R Polymerase GGCCTGTTTACAGGAAGTTTTC 
pBR322_R3-l-R Core CCCAGGTGCTAAAGTCCTCA 
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3.3 Results 
3.3.1 Identification of HBV Integration Sites in Cell Lines 
The PCR products from the nested RS-PCR were examined by gel electrophoresis. 
A representative example of 80 reactions is shown in Figure 3-2. The PCR product of 
each RS-PCR assay was subjected to a first round of DNA sequencing. The sequencing 
result was analyzed online using the BLAST program, where sample sequences were 
aligned with the HBV sequence so as to confirm the presence of the virus. The DNA 
sequence derived was also analyzed by the BLAST program for the possible presence of 
human sequence juxtaposed to HBV. The presence of both HBV and human cellular 
sequences in the same DNA sequence would be suggestive of the likelihood of an HBV 
integrant identification. A second confirmatory DNA sequencing was performed by 
excising the distinctive bands based on the pattern and product size from the gel 
electrophoresis of RS-PCR products (Figure 3-3). Sequence analysis of viral human 
junction and orientation was performed and recorded (Figure 3-4 - Figure 3-5). 
In 15 cell lines examined, one or more HBV integration sites could be found in 13 
cell lines (86.6%). A total of 23 virus host junctions were identified. The corresponding 
chromosomal locations and virus insertion sites are listed in Table 3-2. 
3.3.1.1 Host Junctions 
According to the NCBI BLAST and UCSC BLAT search, exact chromosomal 
locations were determined and mapped for 22/23 virus junctions. The chromosome 
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location of the one flanking sequence isolated from HKCI-8 could not be confirmed due 
to the high content of repetitive sequences that prohibited accurate interpretation. 
In the 22 flanking sites determined, cellular genes or hypothetical protein being 
interrupted by the HBV insertion were determined for 9 sites. Candidate genes localized 
within lOOkb were suggested in 6 cases. For the remaining 8 sites, no known gene or 
hypothetical protein could be identified within lOOkb upstream or downstream of the 
flanking sites. Genes interrupted or located within lOOkb to the HBV integration site are 
listed in Table 3-2. 
3.3.1.2 Viral Junctions 
The open reading frame and the corresponding nucleotide positions in which 
HBV genome was interrupted have been listed in Table 3-2. Based on the analysis of 15 
HBV-related cell lines, the region HBx was found to be involved in most insertions 
(45%). The HBV core is the second most frequently involved site (32%). The 
involvement of polymerase and surface antigen, on the other hand, was less frequent with 
an incidence of 19% and <1% insertional events, respectively. 
3.3.2 Evaluation of RSO Primer Efficiency 
In the investigation of HBV integrants in cell lines, RSO primers corresponding to 
10 restriction site sequences were evaluated. From the results obtained, it was found that 
HBV integrants were most frequently identified using only 6 RSO primers. The highest 
frequency being Hindlll > BamHI > Ndel > Sail > EcoRI > Pvul > Xbal > Taql. Despite 
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1 to 2 integrants being identified using Xbal and TaqI, these integration sites could also 
be determined using RSO primers such as Pvul and Sail. The efficiency of RSO primers 
used is summarized in Figure 3-6. 
The 6 RSO primers, BamHI, EcoRI, Ndel, Hindlll, Pvul and Sail, were hence 
chosen for later examination in primary HCC and the paired surrounding non-malignant 
liver. 
3.3.3 SKY and FISH Analysis 
The result from RS-PCR analysis in Hep3B cells suggested that HBV integration 
occurs at chr. 13q31.3. Previous SKY analysis performed by our lab on Hep3B suggested 
the presence of chromosome translocations, t(l;13), t(6;4;13), t(13;16) (Table 3-3). The 
Spectral Karyotype of Hep3B is shown in Figure 3-7. 
FISH analysis for HBV integration in Hep3B suggested a single event of viral 
insertion at chromosome 13. Inverted DAPI analysis, however, suggested the viral 



















































































































































































































































































Figure 3-3 Gel electrophoresis of SNU475 using Sail as RSO primer 
SNU475 i Sail 
-Mt ick M 
M F1 F2 F3 F4 R1 R2 R3 R4 
• • 
SOObp I==> 
Bands highlighted represent HBV integrants. Although gel showed differences in band 
sizes, they actually represented the same insertional sites. The differences in sizes were 
due to different locations of HBV-specific primer used. 
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Figure 3-4 Sequence result of integrant found in SNU 449 
Core 
• • • • • • 11_1晒_1丨mil 
AATACTCAAGAACiGTTTCTCTQCCAAAAGTftAGiCAGG AAATGTeAftACCACAATAGTTQTCTGATTTTTAGQCCC 
n^  m uo ！ 150 m m 
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CCATATTiACATTC ACATAG C T G AC T AC T A A T TC CC T GG iTGC TG G G TC TT i»T T G T C T TG G T AC AG T Ti TC T T T fT 
181 ^ 2D0 210 520 . 230 giS 250 
iMukdHuMm 
Chr. 10p11.21 ^ 
TTACATGTGTATTGTTTTTCTTCCCTAAATTGAIGTTTTTTGAAGGCAGGG At： TAG 1T T T T AT TC^ ^ T T AC A TA T 丁 ^  C T T 7JQ ^ 2B0 29Q ^ ^ ？ 咖 
(Human) \ 
Sequence analysis was performed on RS-PCR product. BLAST result showed that HBV 
sequence was present in the PGR product isolated from SNU 449 and human sequence at 
chromosomal location 1 Op 11.21 was found to follow the viral sequence. 
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Figure 3-5 Sequence analysis on the human flanking sequence isolated from SNU 
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Flanking human sequence was subjected to BLAT search Oittp://www.genome.iicsc.edu.) 
and the gene interrupted or in the vicinity of the insertion site is indicated. In SNU 387， 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3-6 Efficiency of RSO primers in identifying HBV integrants 
1 2 -1 — 
= s 
3 1—1 










i 2 - — — — — — — ^ 
0 H ~ I ~ ~ I ~ I — — I ~ ~ I ~ — — I — ~ ~ I ~ I 1 
Hindlll 日amHI Ndel Sail EcoRI Pvul Xbal TaqI Sau Alul 
3AI 
A summary of the number of viral integrants identified by individual primers shown. 
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Table 3-3 Chromosomal rearrangements in Hep3B as determined by SKY 
Cell line Karyotype based on SKY 







+ der(4)t(6;4;13)(6?p::4pl4 3 4q21::13q?) x 2 一 






Chromosome 13 translocation events denoted by arrow. 
Figure 3-7 Spectral Karyotype of Hep3B 
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Figure 3-8 TSA-FISH of HBV in Hep3B cell line 
• 
HBV probe labeled with biotin was visualized using FITC-conjugated avidin (green). 
Inverted DAPI analysis suggested HBV insertion at chr. 13ql2 in He3B cells. 
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3.4 Discussion 
In this chapter, the efficiency of RS-PCR in identifying flanking human sequences 
was assessed in HCC cell lines prior to the investigation of primary HCC tumors. The 
result from 15 HCC cell lines investigated, showed 13 cell lines harbor HBV integratants 
(86.6%) and a total of 23 integration sites was found. The percentage of cases where 
HBV integrants can be successfully identified was high, and, thus, suggested the 
feasibility for the RS-PCR technique in further investigations. 
3.4.1 HBV Insertions in HCC Cell Lines 
Based on the results obtained from 15 cell lines studied, recurrent gene 
interruptions were not observed. The chromosomal locations of viral insertional sites 
were also distributed at various sub-chromosomal regions. The diverse locations of virus 
host junctions may imply that HBV does not integrate into the host genome through 
specific genes or chromosomal locations preferentially. However, in 23 flanking 
sequences identified, it was interesting to note that the regions of all interrupted genes 
were at the intronic regions and insertional sites were frequently juxtaposed to repetitive 
sequences such as Alu, SINE and LINE. Further investigations in primary HCC would 
provide a more comprehensive picture of the pattern of HBV integrations and 
substantiation of cell line findings. 
At the HBV junction, it was previously reported that integrations frequently 
occurred through the HBx and core regions (Dejean et al. 1984; Hino et al. 1991). In the 
15 cell lines studied, the X and core regions of the virus were indeed most commonly 
interrupted. It is possible that the translated HBx protein may alter the regulatory 
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pathways of the host, as it is a well-known transactivator of the cellular genes (Graef et al. 
1994). 
3.4.2 Efficacy of RSO primers 
A total of 80 PGR assays (10 RSO primers and 8 HBV primers) were performed 
per cell line in the current study. This number of reactions is too big to handle in a large 
series of investigations and especially in primary HCC, where the DNA material is 
limited. The efficacy of the 10 RSO primers was, therefore, evaluated. It was found that 
frequent HBV integrants can be identified from just six RSO primers that corresponded 
to the restriction sites BamHI, EcoRI, Ndel, Hindlll, Pvul and Sail. Three integrations 
could also be found in the remaining 2/4 RSO primers (Xbal and TaqI). While there is 
the concern that streamlining the number of RSO primers may result in missing some 
viral junctions, results also showed that these integrations identified by the less efficient 
primers could be identified successfully by one or more of the six most efficient RSO 
primers. For RSO primers Sau3AI and Alu, no insertional site could be identified using 
these primers. The six RSO primers that could efficiently locate the viral-host junction 
were, hence, chosen for isolating HBV integrants in primary HCC. 
3.4.3 Investigation of HBV Integration on Chromosomal 
Rearrangement 
In this chapter, HBV insertion in Hep3B cells was investigated by the combined 
analysis of FISH mapping and SKY with an aim to investigate whether chromosome 
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rearrangements occurred at sites of integration. SKY analysis on Hep3B cell lines 
suggested three derivative chr. 13 rearrangements with chr. 1, 4 and 16. FISH analysis 
indicated a single event of HBV insertion. Inverted DAPI analysis of the crude G-banded 
chromosomes suggested the viral insertion at chr. 13ql2. Although both RS-PCR and 
FISH suggested a single viral insertion on chr. 13q，the sub-chromosomal location was 
different. By RS-PCR, flanking human sequences were suggested on chr. 13q31.3. One 
possible explanation could be chromosome 13 in Hep3B may have undergone intra-
chromosomal inversion that was difficult to discern by crude DAPI images. Further 
investigation by dual hybridization of a BAC clone at chr. 13q31.3 and HBV will help to 
elucidate this point. 
Moreover, our present study represented only a single analysis of one cell line. 
Parallel experiments of TSA-FISH followed by SKY analysis on the same metaphase 
chromosomes would allow the confirmation of whether or not HBV insertion into the 
human genome plays a role in chromosomal instability. 
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Chapter 4 
Investigation of Hepatitis B Virus 
Integration Sites in Primary HCC 
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4.1 Introduction 
The successful identification of viral-host junctions in cell lines by RS-PCR 
technique has prompted the further investigations in primary HCC described in this 
chapter. The ten RSO primers used for the study of cell lines were streamlined to six 
primers without influencing the efficiencies in identifying HBV insertions. 
Here, primary HCC and their paired adjacent non-malignant liver were 
investigated for their patterns of HBV integration. Furthermore, cirrhotic and non-
cirrhotic HCC cases were also investigated. It is known that the presence of cirrhosis is 
one of the major risk factors of HCC carcinogenesis, but HCC could also develop in the 
liver without cirrhosis or in chronic hepatitis. This may imply that HBV infection and/ or 
the integration may play a role in the initiation of HCC. However, the effect of HBV 
integrations on HCC development is still not well understood to date. 
In this chapter, a total of 100 specimens were analyzed by RS-PCR (50 pairs of 
primary HCC and their corresponding non-malignant liver from chronic carriers of HBV). 
Thirty-three of them were from tumors arising from a cirrhotic background and the 
remaining 17 cases were from chronic hepatitis or non-cirrhosis. The specific locations of 
genes interrupted or located near the insertional sites were scored. Finally, a combined 
analysis on the viral-human junctions obtained fom primary tumors and cell lines were 
also analyzed with an effort to understand features in both human and virus that may 
have contributed to HCC development. 
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4.2 Materials and Methods 
4.2.1 Patients 
Tumorous liver tissues and corresponding adjacent non-malignant liver tissues 
were obtained from 50 Chinese patients who underwent curative surgery for HCC at the 
Prince of Wales Hospital, Hong Kong. Among these 50 cases, aged 30-74 years (median 
age, 57), male patients were predominant (82%). All patients were serologically positive 
for HBV, and none showed evidence of co-infection with HCV. A diagnosis of HCC and 
the presence or absence of a cirrhotic background was confirmed by an experienced 
pathologist. Thirty-three patients (60%) showed underlying liver cirrhosis. The remaining 
17 patients showed features of chronic hepatitis. The disease stage of tumors collected 
was classified according to the American Joint Committee on Cancer (AJCC) TNM 
staging criteria (Vauthey et al. 2002). Staging criteria included the pathologic 
characteristics of tumor size at greater or less than 5 cm, number and location of tumor 
nodules, presence of vascular invasion, perforation of visceral peritoneum and invasion 
of adjacent organs. The AJCC classification indicated 33 were T2, 12 were stage T3 and 
four were stage T4. Statistical analysis does not suggest differences in clincopathological 
characteristics between patients with or without underlying cirrhosis (p>0.05). 
Clinicopathological information of patients recruited is summarized in Table 4-1. 
The tissues obtained were embedded in Optimal Cutting Temperature Compound 
(OCT) and stored at -80°C until use. Genomic DNA was extracted using QIAGEN DNA 




RS-PCR amplification of primary HCC tumors and surrounding non-malignant 
livers was performed using a combination of 6 RSO primers (BamHI, EcoRI, Ndel, 
Hindlll, Pvul, and Sail) and 8 HBV-specific primers. This generated 48 different PGR 
reactions for each HCC tumor and adjacent liver. The procedures, reaction conditions and 
the sequencing were the same as described previously for HCC cell lines (Section 3.2.2). 
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Table 4-1 Clinicopathological information of HCC patients studied. 
cirrhotic HCC non-cirrhotic HCC p-value 
n = 33 n = 17 
Gender 1.0 
Male 27 (81.8%) 14 (82.4%) 
Female 6(18.2%) 3(17.6%) 
Age 0.486 
Median (range) 56 (30-73) 59.5 (37-74) 
AFP (ng/ml)* 0.697 
median (range) 121 (2-59200) 446 (2.4-21400) 
HBsAg 
Positive 33 17 
AJCC staging* 1.0 
Stage II 24 (72.7%) 9 (52.9%) 
Stage III 6(18.2%) 6 (35.3%) 
Stage IV 3(9.1%) 1 (5.9%) 
*’ Applicable to cases with available information 
Pearson's Chi Square test was used to examine the correlation between gender and tumor 
staging in HCC. Mann-Whitney U test was used to compare differences in age between 
cirrhotic and non-cirrhotic patients. All statistical analysis was performed using SPSS for 
Windows 10.0 software (SPSS Inc., Chicago). 
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4.3 Results 
4.3.1 HBV Integration Sites in Primary HCC Tumors and Adjacent 
Non-malignant Liver 
In 50 paired HCC tumors and their adjacent non-malignant liver tissues examined, 
integrations of HBV were identified in both HCC tumor tissues and the adjacent non-
malignant liver tissues. Examples of gel electrophoresis showing all PCR reactions in a 
case of HCC and paired non-malignant liver are shown in Figure 4-1. Out of 50 cases, 
integrations of HBV could be identified in 27 HCC tumors (54%) and 16 non-malignant 
livers (32%). The percentage incidence of HBV integration sites was higher in tumors 
than adjacent non-malignant livers. Examples of sequencing analysis and online BLAT 
analysis for the human flanking sequence of integrants are shown in Figure 4-2 to Figure 
4-6. 
HBV insertions could also be identified in both cirrhotic and non-cirrhotic tumors. 
Out of 33 cirrhotic HCC tumors examined, HBV integrations were identified in 16 cases 
(48.5%). In the non-cirrhotic group, HBV insertions were found in 11 out of the 17 cases 
(64.7%) examined. In the adjacent non-malignant livers, HBV integration was identified 
in 12 cirrhotic cases (36.4%) but only 4 non-cirrhotic cases (23.5%). The percentage 
incidences of viral integrants identified in tumors and adjacent non-malignant livers are 
summarized in Table 4-2. The percentage incidence between tumor and adjacent non-
malignant liver in non-cirrhotic group demonstrated significant differences (p<0.016). 
One or more integration sites could be found per specimen in the cirrhotic group, 
26 integration sites were identified in the tumorous HCC, while 19 were found in the 
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adjacent livers. For non-cirrhotic cases, 16 HBV insertional sites were found in the HCC, 
but 7 in the adjacent liver. The average incidence per case, however, was similar between 
cirrhotic and non-cirrhotic HCCs, and between tumor and adjacent non-malignant liver. 
In a total 68 virus-host junctions identified, more frequent integrations were 
suggested in tumors (42 flanking sites) compared to non-malignant liver. 
4.3.1.1 Host Junctions 
In 68 HBV integration sites found, exact chromosomal locations could be 
identified for 65 sites. The chromosomal location of the remaining 3 host junctions could 
not be determined due to the presence of extremely short or repetitive sequences. The 
chromosomal locations mapped have been tabulated in Table 4-3 and Table 4-4. 
Although few chromosomal locations have been interrupted more than once, such as 
16q21, 5pl3-5pl5, 2q35-q36 and 8pll.21, these integrants did not involve the same 
nucleotides. 
In the 65 chromosomal locations of integrated sites, known genes were 
interrupted in 23 of them. Known genes or hypothetical proteins located in the vicinity of 
virus-host junctions were suggested in 26 cases. In the remaining 16 insertional sites, no 
known genes or hypothetical proteins could be found within lOOkb upstream or 
downstream of the flanking sites. The genes being interrupted or located within lOOkb of 
the HBV integration sites are summarized in Table 4-3 and Table 4-4. 
Despite the absence of recurrent genes being interrupted by HBV, it was found 
that intronic regions were interrupted in almost all cases with only 2 virus-host junctions 
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found in the exon. This integration pattern concurred with that observed in the cell lines, 
as described in Section 3.3.1. 
4.3.1.2 Viral Junctions 
The viral sequences involved in the insertional events were also examined. The 
insertional nucleotide breakpoint and the viral open reading frame encoded are 
summarized in Table 4-3 - Table 4-4. 
In the cirrhotic cases, HBx was found to be involved in most of the insertion sites 
(47%). The core region was involved in 18%, polymerase in 32% and surface antigen in 
less than 1% of the integration sites identified. In the non-cirrhotic cases, HBV 
integration into the host genome through HBx was also found most frequently (45%). 
The core protein was involved in 1% and polymerase in 41% of the insertion events. The 
results determined in cirrhotic and non-cirrhotic cases suggested the HBV DNA 
integrates mostly through the junction of HBx. These results were similar to that found in 
cell lines, where the HBV preferentially inserted through the 2 DR regions located 


























































































































































































































































































































































































































































Figure 4-2 Example of RS-PCR analysis on primary HCC 
H252 / Ndel 




RS-PCR analysis on H252 using Ndel as the RSO primer. Bands highlighted in red 
circles represent the HBV integrants. 
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Figure 4-3 Examples of sequencing analysis on primary HCC 
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Sequence results of integrant found in (a): H210T and (b): H219T. Direct DNA 
sequencing analysis was performed after RS-PCR. BLAST result showed that in (a) 
H210T, human sequence at the chromosomal location 8pl 1.2land in (b) H219T, human 
sequence at the chromosomal location 12ql2 was identified. 
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Figure 4-4 Example of sequencing analysis on primary adjacent non-malignant liver 
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Sequence results of integrant found in (a): H200N and (b): H144N. Direct DNA 
sequencing analysis was performed after RS-PCR. BLAST result showed that in (a) 
H200N, human sequence at the chromosomal location 20q 11.22 and in (b) H144N, 
human sequence at the chromosomal location 7ql 1.21 was identified. 
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Figure 4-5 Sequence analysis on the human flanking sequence isolated from 
primary HCC 
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Flanking human sequence was subjected to BALT search (http://www.geiiome.ucsc.edu) 
and the gene interrupted or located in the vicinity of the insertional site is indicated. In (a) 
H206T, cellular gene ABCC12 at chr. 16ql2.1 was interrupted by HBV DNA and (b) 
H210T, hypothetical proteins FLJ25169, DKFZp586M1819 and cellular gene ANK 1 at 
chr. 8pl 1.21 were located within lOOkb from the site of integration sites. 
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Figure 4-6 Sequence analysis on the human flanking sequence isolated from 
adjacent non-malignant liver 
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Flanking human sequence was subjected to BALT search (http://www.genome.ucsc.edu) 
and the gene being interrupted or located in the vicinity of the insertion site is indicated. 
In (a) H200N, cellular gene NRGl at chr. 8pl2 was located within lOOkb from the 
integration site, (b) H210N, cellular gene FNl at chr. 2q35 was interrupted by HBV DNA. 
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Table 4-2 HBV integrations in cirrhotic and non-cirrhotic HCC 
(a) Cirrhotic HCC 
Cases with HBV Number of Estimated 
integration identified integrations integration per 
found case 
Tumor 16 /33 (48.5%) 26 1.6 
Adjacent non-
malignant liver 12 /33 (36.4%) 19 1.6 
(b) Non-cirrhotic HCC 
Cases with HBV Number of Estimated 
integration identified integrations integration per 
found case 
Tumor* 11 /17 (64.7%) 16 1.5 
Adjacent non-
malignant liver 4 / 1 7 (23.5%) 7 1.8 
* The percentage incidence between tumor and adjacent non-malignant liver in non-




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4.1 HBV Integration Sites in Primary HCC Tumors and Adjacent 
Non-malignant Liver 
Integration of HBV DNA into the host genome has been reported in 9-22% of 
chronic HBV infected patients (Brechot et al. 1981; Fowler et al. 1986) and in 80% to 
90% of HBV-related HCC (Robinson et al. 1990; Huang et al. 2005). Clonal expansion 
of these integration sites was further observed (Laskus et al. 1999; Ng et al. 2003; 
Paterlini-Brechot et al. 2003). In 50 paired primary HCCs and their adjacent non-
malignant liver tissues, HBV DNA insertions were more frequent in tumors of both 
cirrhotic and non-cirrhotic cases, although this phenomenon was more distinct in the non-
cirrhotic cases. Previous investigation has also suggested that HBV integration occurred 
more frequently in tumors than in non-tumor parts of the livers (Lai et al. 1988). This 
may be due to the fact that malignant cells demonstrate clonal expansion and viral 
integration sites can, hence, be more easily detected. 
4.4.1.1 Host Junctions 
In 50 HCC tumors and adjacent non-malignant liver examined, although several 
genes were found to be interrupted or located near the HBV integration sites more than 
once, they did not show any significant recurrence. 
Similar to the findings in cell lines, results obtained from primary HCC also 
suggested that cellular genes interrupted by HBV insertions commonly occurred at the 
intronic or non-coding regions. This further indicates that the insertions of viral genome 
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into the introns of the genes are preferred. However, the consequences of disrupting 
intronic regions of the genes remain to be defined. One of the possible influences of 
disrupting the introns of the genes could be an alteration in the transcriptional regulation 
of the cellular genes responsible for specific biological function. This might in turn affect 
the level of the protein translation or the translated normal function. 
Integration of HBV DNA was not restricted to tumor cells，clonally expanded 
cells containing integrated HBV-DNA molecules could also be identified in the non-
tumorous, adjacent livers. The identification of HBV DNA insertions in the cirrhotic liver 
has also been suggested from early Southern blot analysis (Brechot et al. 1981) and the 
pattern derived from the non-tumor counterpart differed from the corresponding tumor. 
The integration sites found in the tumor and adjacent non-malignant livers in this study 
were often dissimilar. The present finding and previous analysis, thus, suggested the 
coexistence of different clones in the HBV infected liver. Moreover, since integrations 
could also be found in chronic HBV carriers with no evidence of HCC (Brechot et al. 
1981; Brechot et al. 1981; Shafritz et al. 1981; Kam et al. 1982; Hadziyannis et al. 1983; 
Brechot 1987; Yaginuma et al. 1987; Yasui et al. 1992), this implied that viral 
integrations are likely to precede the development of tumor (Shafritz 1982). Integrations 
of HBV into the hepatocytes might represent initial events in increasing the risk of HCC 
development by conferring clonal advantages. 
Only few studies have examined to date the viral integration patterns in HCC 
arising from a cirrhotic and non-cirrhotic background. In this chapter, the HBV 
integrations between the two groups were examined for potential differences in the 
pattern of viral insertion. Our results showed that the HBV insertion into human genome 
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is more frequent in non-cirrhotic than cirrhotic tumors (Table 4-2). Moreover, 
integrations found in tumors were significantly higher compared to adjacent non-
malignant livers in the non-cirrhotic group than in the cirrhotic group (p<0.016) (Table 4-
2). This might imply that there could be higher impact of HBV integrations in non-
cirrhotic cases. 
4.4.1.2 Viral Junctions 
The results from the primary HCC tissues and their adjacent non-malignant liver 
tissues analysis were similar to that found in HCC cell lines. HBV DNA insertion into the 
host frequently occurred through the HBx region of the vims. No significant difference in 
the viral junctions was observed between the cirrhotic and non-cirrhotic group and 
between the tumor and adjacent non-malignant liver. This suggested that there is a 
preferential region of HBV insertion during integration into the host through the HBx. 
The expression of viral oncoproteins, in particular HBx, is well-recognized in the 
modulations of cell proliferation and viability (Andrisani and Barnabas 1999; Diao et al. 
2001). HBx protein has been suggested in the stimulation of signal transduction pathways 
earlier on in the carcinogenesis of HCC. HBx is also reported to act as a trans-activator of 
the cells and can initiate several cellular promoters and upregulation of different cellular 
genes. 
In summary, HBV integration into the host genome might induce abnormal 
physiological functions compared to normal hepatocytes, which in turn will put host cells 
at risk of further malignant development. 
90 
4.4.2 Summary on HBV Integrants Identified 
Integrations of HBV into the human genome were observed in HCC cell lines, 
primary HCC and adjacent non-malignant livers, totaling 91 HBV integration sites 
identified. A summary of HBV integrants identified is shown in Table 4-5. 
4.4.2.1 Preferential Fragile Sites Insertion 
It is well known that fragile sites are highly unstable chromosome regions that are 
prone to breakage and rearrangements. Integration of human papillomavirus (HPV) into 
common fragile sites has been described in cervical tumors (Thorland et al. 2000) and 
preferentially by the HPV 16 (Thorland et al. 2003). In an attempt to understand whether 
or not HBV integrations also preferentially inserted at common fragile sites, the locations 
of virus host junctions identified in this study and from a recently reviewed large cohort 
of study by (Murakami et al. 2005) were correlated with the location of known fragile 
sites. It was found that a number of integration sites identified in HCC cell lines and 
primary HCC overlapped with common fragile sites (Figure 4-7). As fragile sites are 
highly recombinogenic regions, the integration at these regions may well have enhanced 
sister chromatid exchange, translocations and/or intrachromosomal gene amplification. 
The accumulation of chromosomal aberrations might lead to increased genomic 
instability that promoted the carcinogenic events of HCC. Although a recent study by 
(Minami et al. 2005) has reported that insertion of HBV DNA into chromosome 3 was 
preferential (Minami et al. 2005), the data found in this study and others did not suggest 
specific chromosomes that favored integrations at a significant frequency. 
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4.4.2.2 Preferential integration into repetitive sequences 
From the human flanking sequences isolated, it was found that repetitive 
sequences of different types such as SINE, LINE and satellites, were frequently observed 
at the viral integrants, irrespective of cellular gene interruption or chromosome locations. 
Since AT content is predominant in repetitive sequences, the AT content within 50bp to 
lOObp of the flanking human sequences was, hence, considerably higher than the GC 
content. It was also previously suggested that integration of HBV into human repetitive 
sequences was more common (Zhou et al. 1988; Tsuei et al. 1994; Wang et al. 2001). 
One possible explanation for this phenomenon could be that A-T regions harbored 
weaker bonding than G-C sites, and, thus, might facilitate viral DNA integrations through 
easier breakage of bonds. 
4.4.2.3 Cellular Genes Affected 
Insertional mutagenesis has been described in HBV integration at specific sites of 
endogenous genes such as retinoic acid p-receptor (Dejean et al. 1986)，cyclin A (Wang 
et al. 1990) and mevalonate kinase (Graef et al. 1994). These findings suggested that viral 
• integration in the vicinity of genes controlling cell proliferation, viability and 
differentiation could be a likely mechanism involved in HBV hepatocarcinogenesis 
(Ferber et al. 2003; Paterlini-Brechot et al. 2003). 
In this study, insertion at chr. 5p 15.33 was among the most frequent events and 
the human telomerase reverse transcriptase (hTERT) gene locates at the proximity of this 
region. Previous studies on HBV integrations have also reported that hTERT was 
interrupted or situated near the HBV integration sites (Ferber et al. 2003; Paterlini-
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Brechot et al. 2003). hTERT is known to be over-expressed in a number of cancers 
(Jeong Seo et al. 2004; Takuma et al. 2004; Liu et al. 2006)，including HCC (Takuma et 
al. 2004). 
Cellular genes, fibronectin 1 (FNl) and myeloid/ lymphoid or mixed-lineage 
leukemia 4 (MLL4) (Murakami et al. 2005), are two genes that were identified in our 
study and reported by other groups in the HBV integration. FNl encodes fibronectins, 
which bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, 
and actin. It is involved in cell adhesion and migration processes (Leeb et al. 2004)， 
wound healing, host defense, and metastasis. FNl has been reported to playa an 
important role in the large B-cell lymphoma development (Lossos et al. 2004). MLL4 
belongs to MLL (mixed-lineage leukemia) family. It is amplified in many solid tumor 
cell lines and likely acts as a transcriptional transactivator of cellular genes in human 
malignancies (Zeisig et al. 2003); (Huntsman et al. 1999). Previous studies have been 
reported that the MLL family was involved in the pathogenesis of leukemia (Gilliland et 
al. 2004). 
The disruption of the cellular genes during HBV integrations might, therefore, 
play a role in disturbing the normal biological functions of host cells and subsequently 
the risk of developing HCC. 
4.4.2.4 Viral Junctions 
In this study, HBV sequences at the virus host junctions have been summarized 
and the HBV nucleotides of the flanking sites are plotted in Figure 4-8. It was found that 
HBV commonly inserted into host genome through a 500bp sequence, spanning from nt. 
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1600 to nt. 2100. This SOObp encodes the HBx and core gene of the virus, and it is 
possible that as a result of insertion, a truncated form of HBx could be generated. It is 
well known that HBx, as well as its truncated form, play a significant role in HCC 
carcinogenesis (Twu and Schloemer 1987; Shirakata et al. 1989; Idilman et al. 1998; 
Feitelson 1999; Brechot et al. 2000). HBx in its truncated form can encode a functionally 
active trans-activator protein (Paterlini et al. 1995) that can transform mouse fetal 
hepatocyes to a malignant phenotype (Henkler and Koshy 1996). Truncated HBx protein 
has been suggested in the stimulation of signal transduction pathways earlier on in the 
carcinogenesis of HCC. Moreover, HBx has been shown to complex with p53 tumor 
suppressor gene thereby inactivating the apoptotic function of p53 (Chen et al. 1993; 
Wang et al. 1994; Truant et al. 1995; Feitelson et al. 1993; Wang et al. 1994; Huo et al. 
2001). HBx protein has also a suggested role in modulating cell proliferation and 
differentiation through the induction of insulin-like growth factor-II and transforming 
growth factor-P expressions (Fu et al. 1988; Yoo et al. 1996). 
It was previously reported that the COOH-terminal part of the HBx protein plays 
a key role in regulating its transcriptional activity and control of cell viability and 
proliferation. Furthermore, HBx mutants with a COOH-terminal deletion have been 
shown to enhance transforming ability of ras and myc (Tu et al. 2001). Findings from this 
study suggested a deletion of about 70 amino acids from the C-terminus of the HBx was 
common in HCC. The anti-apoptotic function of HBx is sensitive to amino acid changes 
in the COOH terminus and increasing evidence suggested that the anti-apoptotic effect 
might be a property of hepatocytes containing large deletions of HBx (>16a.a.) (Tu et al. 
2001). 
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Table 4-5 Summary of HBV integrations identified in cell lines and primary HCC 
Number of cases Percentage of Total number 
HBV HBV of HBV 
Total integration integration integration 
site identified identified sites 
HCC Cell 
lines 15 13 86.7 23 
Primary HCC 50 27 54 42 
Adjacent non-
malignant 
liver 50 16 32 26 




















































































































































































































































































































































































































































































































































































































































































































Proposed Future Studies 
98 
The results from this thesis provide information on the location of HBV 
integration sites. On summarizing the data generated, although recurrent insertion sites 
were not suggested, insertions into the cellular genes at the intronic or non-coding regions 
were found and integration sites were often near/ within repetitive sequences. Also, the 
HBx and core gene of the HBV were regions frequently being interrupted in the viral 
junctions. Below are further studies propose for future investigations. 
5.1 Correlation of Structural Aberrations with HBV Integrations 
It was mentioned in previous studies that HBV insertion into the host genome 
could induce genomic instability and, hence, promote chromosomal rearrangements in 
HCC (Hino et al. 1986; Su et al. 1998). In order to confirm this postulation, the location 
of insertional sites and structural abnormalities should be investigated simultaneously. In 
view of this, a parallel study on SKY analysis followed by TSA-FISH for HBV could be 
performed on HCC cell lines. This will allow visualization of the inserted HBV location 
and chromosomal aberrations found in the same metaphase. The results obtained should 
provide information of HBV integration and chromosomal rearrangements, and enable us 
to directly correlate between viral insertion and chromosome instability. 
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5.2 Transcriptional Expression Study on the Genes Interrupted 
by or Located Near the Virus Host Junctions 
Preliminary examination of the transcription expression of genes being 
interrupted or located near the HBV integration sites by quantitative RT-PCR has been 
carried out, although not highlighted in the text. The results obtained on a small series of 
5 integrants could not give conclusive information on gene expression following HBV 
insertion. Therefore, further investigations at the mRNA and protein levels may be 
required to be carried out in a larger series of samples in order to define the effect of viral 
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